Higher plasma high-mobility group box 1 levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: A 12 year follow-up study

Nin, J. W. M., Ferreira, I., Schalkwijk, C. G., Jorsal, A., Prins, M. H., Parving, H. -H., Tarnow, L., Rossing, P. and Stehouwer, C. D. A. (2012) Higher plasma high-mobility group box 1 levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: A 12 year follow-up study. Diabetologia, 55 9: 2489-2493. doi:10.1007/s00125-012-2622-1


Author Nin, J. W. M.
Ferreira, I.
Schalkwijk, C. G.
Jorsal, A.
Prins, M. H.
Parving, H. -H.
Tarnow, L.
Rossing, P.
Stehouwer, C. D. A.
Title Higher plasma high-mobility group box 1 levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: A 12 year follow-up study
Journal name Diabetologia   Check publisher's open access policy
ISSN 0012-186X
1432-0428
Publication date 2012
Year available 2012
Sub-type Article (original research)
DOI 10.1007/s00125-012-2622-1
Open Access Status
Volume 55
Issue 9
Start page 2489
End page 2493
Total pages 5
Place of publication Heidelberg, German
Publisher Springer
Language eng
Abstract Aims/hypothesis: This study aimed to investigate the associations of plasma levels of the pro-inflammatory cytokine high-mobility group box 1 (HMGB1) with incident cardiovascular disease (CVD) and all-cause mortality in patients with type 1 diabetes. Methods: We prospectively followed 165 individuals with diabetic nephropathy and 168 individuals with persistent normoalbuminuria who were free of CVD at study entry and in whom levels of HMGB1 and other cardiovascular risk factors were measured at baseline. Results: During the course of follow-up (median, 12.3 years [interquartile range, 7.8-12.5]), 80 patients died, 82 suffered a fatal (n = 46) and/or non-fatal (n = 53) CVD event. After adjustment for age, sex, case-control status and other risk factors, patients with higher levels of loge HMGB1 had a higher incidence of fatal and non-fatal CVD and all-cause mortality: HR 1.55 (95% CI 0.94, 2.48) and HR 1.86 (95% CI 1.18, 2.93), respectively. Further adjustments for differences in markers of low-grade inflammation, endothelial and renal dysfunction and arterial stiffness did not attenuate these associations because plasma levels of HMGB1 were not independently associated with these variables. Conclusions/interpretation: In patients with type 1 diabetes, higher levels of plasma HMGB1 are independently associated with a higher risk of all-cause mortality and, to a lesser extent, with a higher incidence of CVD. Larger studies are needed to ascertain more definitely the role of HMGB1 in the development of vascular complications in diabetes.
Keyword All Cause Mortality
Cardiovascular disease
High mobility group box 1
Type 1 diabetes mellitus
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Public Health Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 12 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 12 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 20 May 2015, 22:18:49 EST by Isabel Ferreira on behalf of School of Public Health